FSLY

FASTLY (FSLY) CEO and CTO Sell $2.1M in Stock in Same Week

Two Fastly insiders, CEO Charles Lacey Compton III and CTO Artur Bergman, sold a combined $2.08 million of Class A shares on 14 and 15 September.

Source: Wikimedia

Two of the most senior insiders at Fastly (FSLY) sold stock in the open market on the same days, according to two Form 4 filings submitted on 16 September. Chief Executive Charles Lacey Compton III and Chief Technology Officer Artur Bergman, both also directors, disposed of a combined total of about $2,081,423 worth of Class A common stock on 14 and 15 September.

A utility-scale solar farm of the type planned under the Tadaa and Kainan partnership.

TREASURE GLOBAL (TGL) Unit Joins $367M, 360 MW Malaysian Solar Farm Project

Tadaa Technology will supply the AI backbone for a 1,000-acre solar farm feeding a data centre under a 25-year power arrangement, targeting $7.3M in annual revenue.

A natural gas wellhead of the kind found across Pennsylvania's Marcellus shale.

ALPHA COMPUTE (ALP) Buys 300 Acres of Pennsylvania Gas Land for $5.5M

Alpha Compute has signed definitive agreements for Utica and Marcellus acreage with more than 75 wells, and plans to build a data center on the site.

Palisade Bio is developing an oral prodrug aimed at inflammatory bowel disease.

FDA Clears PALISADE BIO IND for PALI-2108 in Crohn's Disease

Palisade Bio can start the Phase 2 ASCENTRA-CD trial of its oral PDE4 prodrug, with first dosing targeted for Q1 2027 and a primary readout in Q1 2028.

PDS Biotechnology is seeking a partner to fund Phase 3 development of its HPV16-targeted immunotherapy PDS0101.

PDS (PDSB) BIOTECH Phase 2 Data Published in JAMA Oncology With 39.3-Month Survival

VERSATILE-002 results for PDS0101 plus pembrolizumab show 39.3 months median overall survival in checkpoint-inhibitor-naive HPV16-positive head and neck cancer.

Read more

TREASURE GLOBAL (TGL) Unit Joins $367M, 360 MW Malaysian Solar Farm Project

ALPHA COMPUTE (ALP) Buys 300 Acres of Pennsylvania Gas Land for $5.5M

FDA Clears PALISADE BIO IND for PALI-2108 in Crohn's Disease

PDS (PDSB) BIOTECH Phase 2 Data Published in JAMA Oncology With 39.3-Month Survival